After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

MicroAlgo Inc. announced its research on the Quantum Information Recursive Optimization (QIRO) algorithm, which aims to address complex combinatorial optimization problems using quantum computing.

Researchers at FIU’s College of Engineering and Computing have developed an encryption algorithm to defend videos from attackers with access to the world's most powerful computers. The encryption ...

ABSTRACT: In this paper, we investigate the convergence of the generalized Bregman alternating direction method of multipliers (ADMM) for solving nonconvex separable problems with linear constraints.

HONG KONG, Oct 2 (Reuters Breakingviews) - It's been two years since ChatGPT made its public debut, kicking off a rush to invest in generative artificial intelligence. The frenzy has lifted valuations ...

For years, drug developers that apply artificial intelligence (AI) have touted the benefits of the technology—the prospect of speedier development of new treatments at lower cost, thus reducing the ...